Luigi Buonaguro

Best Publications

• Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.

  B Ensoli;L Buonaguro;G Barillari;V Fiorelli

  995
  Citations

• Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications

  L. Buonaguro;M. L. Tornesello;F. M. Buonaguro

  567
  Citations

• HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

  Hsiao C. Chang;Felipe Samaniego;Felipe Samaniego;Bala C. Nair;Luigi Buonaguro

  557
  Citations

• Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

  Joris Hemelaar;Ramyiadarsini Elangovan;Jason Yun;Leslie Dickson-Tetteh

  408
  Citations

• Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines.

  Luigi Buonaguro;Giovanni Barillari;Hsiao K. Chang;Cindy A. Bohan

  382
  Citations

• Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities.

  Anna Lucia Tornesello;Antonella Borrelli;Luigi Buonaguro;Franco Maria Buonaguro

  354
  Citations

• Translating Tumor Antigens into Cancer Vaccines

  Luigi Buonaguro;Luigi Buonaguro;Annacarmen Petrizzo;Maria Lina Tornesello;Franco M. Buonaguro

  294
  Citations

• Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis.

  Giovanni Barillari;Luigi Buonaguro;Valeria Fiorelli;John Hoffman

  244
  Citations

• Mutations in TP53 , CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections

  Maria Lina Tornesello;Luigi Buonaguro;Fabiana Tatangelo;Gerardo Botti

  209
  Citations

• Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies.

  Francesca Pezzuto;Luigi Buonaguro;Francesco Caponigro;Franco Ionna

  205
  Citations

• The Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer.

  Maria Lina Tornesello;Raffaella Faraonio;Luigi Buonaguro;Clorinda Annunziata

  198
  Citations

• Antigen-specific vaccines for cancer treatment.

  Maria Tagliamonte;Annacarmen Petrizzo;Maria Lina Tornesello;Franco M Buonaguro

  187
  Citations

• Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer.

  Maria Lina Tornesello;Luigi Buonaguro;Paolo Giorgi-Rossi;Franco M. Buonaguro

  176
  Citations

• The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure.

  Luigi Buonaguro;Franco M. Buonaguro;Gaetano Giraldo;Barbara Ensoli

  170
  Citations

• Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses

  L. Buonaguro;M. L. Tornesello;M. Tagliamonte;R. C. Gallo

  153
  Citations

• Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma

  Markus W. Löffler;Christopher Mohr;Leon Bichmann;Lena Katharina Freudenmann;Lena Katharina Freudenmann

  142
  Citations

• Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?

  Piera Gargiulo;Chiara Della Pepa;Simona Berardi;Daniela Califano

  142
  Citations

• Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

  C. A. Bohan;F. Kashanchi;B. Ensoli;L. Buonaguro

  137
  Citations

• High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts

  Nunzia Scotti;Fiammetta Alagna;Enrico Ferraiolo;Gelsomina Formisano

  132
  Citations

• Selecting Target Antigens for Cancer Vaccine Development.

  Luigi Buonaguro;Maria Tagliamonte

  128
  Citations

• Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.

  L. Buonaguro;M. L. Visciano;M. L. Tornesello;M. Tagliamonte

  114
  Citations